Jacobs Levy Equity Management
CBIO

Jacobs Levy Equity Management’s Crescent Biopharma CBIO Stock Holding History

Jacobs Levy Equity Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,650
Closed -$799K – 1013
2021
Q3 		$799K Buy
3,650
+360
+11% +$76.2K 0.01% 798
2021
Q2 		$763K Sell
3,290
-1,075
-25% -$274K 0.01% 797
2021
Q1 		$1.31M Buy
4,365
+1,181
+37% +$423K 0.01% 679
2020
Q4 		$1.2M Buy
3,184
+881
+38% +$309K 0.01% 678
2020
Q3 		$707K Sell
2,303
-588
-20% -$225K 0.01% 723
2020
Q2 		$1.09M Buy
2,891
+2,035
+238% +$576K 0.01% 655
2020
Q1 		$195K Buy
856
+302
+55% +$115K ﹤0.01% 891
2019
Q4 		$293K Buy
+554
New +$300K ﹤0.01% 858
2017
Q1 		– Sell
-192
Closed -$117K – 946
2016
Q4 		$117K Sell
192
-74
-28% -$46.2K ﹤0.01% 886
2016
Q3 		$190K Sell
266
-21
-7% -$16.1K ﹤0.01% 917
2016
Q2 		$208K Buy
287
+14
+5% +$9.65K ﹤0.01% 1005
2016
Q1 		$162K Sell
273
-6
-2% -$3.08K ﹤0.01% 996
2015
Q4 		$160K Buy
279
+103
+59% +$68.3K ﹤0.01% 712
2015
Q3 		$99K Sell
176
-121
-41% -$87.4K ﹤0.01% 761
2015
Q2 		$236K Buy
+297
New +$246K ﹤0.01% 700

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Jacobs Levy Equity Management's CBIO Position: Q4 2021 in Review

Jacobs Levy Equity Management sold out of Crescent Biopharma (CBIO) in Q4 2021, closing a stake of 3,650 shares — an estimated $799K sold.

Jacobs Levy Equity Management first reported a position in CBIO in Q2 2015 and held it in 15 quarters. The position peaked at $1.31M in Q1 2021. 47 funds tracked by Wall St. Rank hold CBIO as of Q4 2021.

  • Jacobs Levy Equity Management reported no remaining Crescent Biopharma position as of Q4 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 3,650 Crescent Biopharma shares in Q4 2021, an estimated $799K.
  • Jacobs Levy Equity Management first reported a position in Crescent Biopharma in Q2 2015 and held it in 15 quarters.
  • Jacobs Levy Equity Management's Crescent Biopharma position peaked at $1.31M in Q1 2021.
  • 47 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2021, filed 14 Feb 2022.